Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease

Journal of Clinical Hypertension

Volumn 11, Issue 5, 2009, Pages 260-265

  Perrone Filardi, Pasquale ^a   Corrado, Luigi ^a   Brevetti, Gregorio ^a   Silvestro, Antonio ^a   Dellegrottaglie, Santo ^a   Cafiero, Maria ^a   Caiazzo, Gianluca ^a   Petretta, Andrea ^a   Maglione, Antonio ^a   Monda, Cinzia ^a   Guerra, Giuseppina ^a   Marzano, Antonio ^a   Cesarano, Paolo ^a   Gargiulo, Paola ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; METOPROLOL; PLACEBO;

ADULT; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; TETRAZOLES; VASODILATION;

EID: 66649117436     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00108.x     Document Type: Article

References (22)

1. Ross E. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Quyyumi AA. Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am J Med. 1998;105:S32-S39.
3. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
4. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
5. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
6. Brevetti G, Silvetsro A, Schiano V, et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease. Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093-2098.
7. Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease. A study of women with chest pain and normal coronary angiograms. Circulation. 2004;109:2518-2523.
8. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.
9. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes. Further evidence foe the existence of the "vulnerable" patient. Circulation. 2004;110:1926-1932.
10. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258-265.
11. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension. 2000;35:501-506.
12. Isobe N, Taniguchi K, Oshima S, et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J. 2002;66:993-999.
13. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002;22:1208-1212.
14. Hornig B, Kohler C, Schlink D, et al. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/ B2-receptor-dependent mechanism. Hypertension. 2003;41:1092-1095.
15. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697-701.
16. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
17. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg. 2003;38:374-379.
18. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-1160.
19. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905-910.
20. Hornig B, Landmesser U, Kobler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease. Role of superoxide dismutase. Circulation. 2001;103:799-805.
21. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
22. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:362-368.